Related Experiment Video
Updated: Apr 2, 2026
09:21
Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
11.9K
Androgen receptor profiling predicts prostate cancer outcome
Suzan Stelloo1, Ekaterina Nevedomskaya2, Henk G van der Poel3
1Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
EMBO Molecular Medicine
|September 29, 2015
Summary
Researchers identified a nine-gene expression signature for predicting prostate cancer outcomes. This discovery offers a new pipeline for identifying prognostic biomarkers in oncology.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Prostate cancer is a leading male malignancy requiring improved prognostic markers.
- Accurate outcome prediction is crucial for tailored postoperative monitoring of high-risk patients.
Purpose of the Study:
- To identify novel prognostic markers for prostate cancer progression.
- To determine the role of chromatin state and androgen receptor binding in tumor development and therapy resistance.
Main Methods:
- Assessed changes in chromatin state during prostate cancer development and progression.
- Performed genomewide androgen receptor/chromatin binding analysis.
- Integrated multilevel genomic data (chromatin accessibility, transcriptional regulation) with public transcriptomic and clinical datasets.
Main Results:
- Identified distinct androgen receptor/chromatin binding profiles in primary versus therapy-resistant prostate cancers.
- Discovered a gene expression signature with strong prognostic potential, refined to nine key genes.
- Validated the nine-gene signature across multiple independent patient cohorts.
Conclusions:
- A novel nine-gene expression signature accurately predicts prostate cancer patient outcomes.
- The study proposes a new, implementable pipeline for biomarker discovery in oncology using integrated genomic data.
